Outpost Medicine expands senior leadership team
Nancy Martin is named as Senior Vice President, Chief Medical Officer.
Dr. Martin most recently served as Vice President, Clinical Development Biosimilars at Pfizer, which she joined through the acquisition of Hospira where she substantially built out the clinical development organization.
Prior to Hospira, she spent six years with Astellas Pharma in roles of increasing responsibility, most recently as Senior Medical Director, Scientific and Medical Affairs with a focus on the urology therapeutic area.
During her tenure at Astellas, Dr. Martin led the clinical development of mirabegron through Phase II, III, and global regulatory approvals for the treatment of overactive bladder. She also led the medical affairs team through product launch.
Previously, Dr. Martin held roles in clinical pharmacology at Aventis and Hoffman-La Roche.
She earned her M.D. from the University of Medicine and Dentistry of New Jersey and Pharm.D. from the University of Illinois at Chicago.
Gordon McMurray is named as Chief Scientific Officer.
Dr. McMurray joined Outpost from Pfizer where he was most recently Head of Pharmacology for the Neuroscience and Pain Research Unit.
He previously served in multiple Research Project and Team Leader roles in both the Pain and Sensory Disorders Research Unit and the Genitourinary and Sexual Dysfunction Research Unit.
During that time, Dr. McMurray led multiple research programs targeting important urologic diseases and conditions, including stress urinary incontinence, overactive bladder and interstitial cystitis.
Prior to Pfizer, he was Lecturer in Pharmacology and Laboratory Head in the Department of Pharmacology at Oxford University where he was a member of the Oxford Continence Group.
Dr. McMurray holds a B.Sc. and Ph.D. from Queen’s University Belfast.
Gale Kennedy is named as Vice President, Clinical Development.
Ms. Kennedy most recently served as Senior Director, Clinical Science at Takeda. During that time, she had clinical leadership responsibilities for multiple clinical-stage urology programs, including OP-233 (formerly TAK-233).
Prior to Takeda, Ms. Kennedy was Programme Director at Plethora Solutions where she led Phase III development for a sexual dysfunction program.
Earlier in her career, she held roles of increasing responsibility in clinical pharmacology and clinical development at Ono Pharmaceutical, AstraZeneca, and Sanofi.
Ms. Kennedy holds a B.Sc. in Biochemistry and Pharmacology from the University of Strathclyde.
Mike Ramsay is named as Vice President, Manufacturing.
Mr. Ramsay joined Outpost from The Medicines Company, which he joined through the acquisition of Incline Therapeutics where he was Senior Vice President, Manufacturing and Supply Operations.
Prior to Incline, he was Senior Vice President, Manufacturing Operations at Cell Genesys with responsibility for three GMP manufacturing facilities.
Previously, Mr. Ramsay served as Vice President, Transdermal Manufacturing at ALZA Corporation.
He has also held various positions with SEQUUS Pharmaceuticals, including Vice President, Manufacturing Operations, as well as various positions at Syntex Corporation focusing on manufacturing, product development and regulatory affairs.
Mr. Ramsay holds a Bachelor of Pharmacy degree from the University of Nottingham. ■